GBT Reports Fourth Quarter and Full Year 2021 Financial Results
Achieved Oxbryta® net revenues of $56.1 million in the fourth quarter and $194.7 million for full year 2021,... | February 23, 2022
Related Keywords
United States , Norway , Ministry Of Health , Dubayy , United Arab Emirates , Iceland , Liechtenstein , United Kingdom , Great Britain , American , Steven Immergut , Courtney Roberts , Alain Romero , Sickle Cell Disease Research , Research Collaborative Data Hub , Galien Foundation , American Society Of Hematology , European Union , Blood Institute , National Heart , Centers For Disease , Bloomberg , Drug Administration , European Commission , Regulatory Agency , Global Blood Therapeutics Inc , Exchange Commission , Securities Exchange , European Medicines Agency , Fourth Quarter , Full Year , Blood Therapeutics , New Drug Application , American Society , Annual Meeting , Marketing Authorization Application , Early Access , Medicines Scheme , Collaborative Data Hub , Convertible Senior Notes , Pharmakon Advisors , Gender Equality Index , South Asian , Southern European , Middle Eastern , Oxbryta Breakthrough Therapy , Fast Track , Orphan Drug , Rare Pediatric Disease , Galien United States , Priority Medicines , Promising Innovative Medicine , Marketing Authorization , Important Safety Information , Prescribing Information , Patient Information , Private Securities Litigation Reform Act , Securities Act , Securities Exchange Act , Quarterly Report , Disease Control , Cell Disease , Accessed February , Rev Dis , San Francisco , Global Blood Therapeutics , Consolidated Statements , Months Ended December , Ended December , Nc Stock Exchange , News , Information , Press Release , Nbt , Reports , Fourth , Quarter , End , Bull , Ear , 021 , Financial , Chieved , Pet , Revenues , F , Billion , N , The , Or , Ear Gbt Us37890u1088 ,
comparemela.com © 2020. All Rights Reserved.